Scientific Publications

On this page you find a selection of scientific publications relating to the product candidates and platform technologies of MOLOGEN AG.

2017
The TLR 9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colonKrarup et. al MucosalImmunology (2017), doi: 10.1038/mi.2017.59Link
TLR9 agonists: Can they exact a toll on HIV persistence?Cyktor, C et al. Clinical Infectious Diseases (2017), Clin Infect Dis cix204.Link
Short-course TLR9 agonists treatment impacts innate immunity and plasma viremia in individuals with HIV infectionVibholm, L et al. Clinical Infectious Diseases (2017), Clin Infect Dis cix201.Link
2016
Distinct immunological activation profiles of dSLIM® and ProMune® depend on their different structural contextKapp, K et al. Immunity, Inflammation and Disease (2016), doi: 10.1002/iid3.126Link
A novel toll-like receptor-9 agonist, MGN1703, enhances HIV-1 transcription and NK cell-mediated inhibition of HIV-1 infected autologous CD4+ T cells                Offersen, R et al. Journal of Virology (2016), doi: 10.1128/ JVI00222-16Link
Design and characterization of the tumor vaccine MGN1601,allogeneic fourfold gene-modified vaccine cell combined with a TLR-9 agonistVolz, B et al. Molecular Therapy - Oncolytics (2016) 3, 15023; doi: 10.1038/mto.2015.23Link
 2015

MIDGE technology for the Production of a Fourfold Gene-Modified, Allogenic Call-Based Vaccine for Cancer Therapy

Schmidt M et al. Gene Therapy of Solid Cancers, Methods in Molecular Biology, Volume 1317, 2015, pp 39-51Link

Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate.

Seifert K et al. Antimicrob. Agents Chemother. 2015 0 (2015), p. AAC. 00273-15v1Link
Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma.Mählmann K et al. BMC Veterinary Research 2015, 11:107 doi: 10.1186/s 12917-015-0414-9Link
Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703.Schmidt M et al. Nucleic Acid Therapeutics.                doi:10.1089 / nat.2015.0533.Link
Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccineRiede O et al. Gene Therapy advance online publication 30 April 2015; doi: 10.1038/gt.2015.35Link
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside.Wittig B et al.Critical Reviews in Oncology/Hematology, 2015.Link
Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. Weihrauch MR et al.Eur J Cancer 51 (2): 146–156, 2015.Link
 
2014
A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703.J. Riera-Knorrenschild et al.
Ann. Oncol., 25 (suppl. 2): ii8 (abstract PD-0009), 2014.
Link
The randomized phase III IMPALA study: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal cancer carcinoma.D. Cunningham et al.
Ann. Oncol., 25 (suppl. 2): ii98 (abstract PD-0268), 2014.
Link
ASET study: Final results of patients with locally recurrent or metastatic renal cell carcinoma (RCC) treated with MGN1601.V. Grünwald et al.
Ann. Oncol., 25 (suppl. 4): iv366-iv367 (abstract 1063P), 2014.
Link
IMPACT study: A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703.W. Scheithauer et al.
Ann. Oncol., 25 (suppl. 4): iv366 (abstract 1061P), 2014.
Link
Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal carcinoma - the randomized phase III IMPALA study.D. Arnold et al.
Ann. Oncol., 25 (suppl. 4): iv371 (abstract 1077TiP), 2014.
Link
Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity
of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine
Endmann A et al.
DOI:10.1371/journal.pone.0101715,  July 2014
Link
Genuine Immunomodulation with dSLIM.Kapp K et al.
Molecular Therapy - Nucleic Acids (2014) 3, e170, epub June 24, 2014
Link
IMPACT trial – Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma.Riera-Knorrenschild J
et al.

J Clin Oncol. 32 (suppl.): 5s (abstract: 3615), 2014
Link
Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. Schmoll HJ et al.
J Cancer Res Clin Oncol. [Epub ahead of print, 2014 May]
Link
Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Studies on formulation, biodistribution and vector clearance.Endmann A et al.
Vaccine. 2014; 32(27): 3460-7
Link

Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector.Kobelt D et al.
Mol Oncol. 2014; 8(3):609-19
Link
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis.Das S et al.
Sci Transl Med. 2014; 6(234): 234-56
Link
Conformation overrides base sequence - insights
from a novel class TLR-9 agonists.
Kapp K et al.
AACR 2014,
abstract no. 2565
Link
ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601.Grünwald V et al.
J Clin Oncol. 32 (4, suppl.): (abstract LBA399), 2014
Link

2013
Updated results of the randomized phase 2 IMPACT trial: Maintenance with TLR-9 agonist MGN1703 vs placebo in patients with metastatic colorectal carcinoma (mCRC).Schmoll HJ et al.
Ann Oncol. 24 (suppl . 4): iv16-iv17 (abstract: O-0012), 2013
Link
Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT).Riera-Knorrenschild J
et al.
J Clin Oncol. 31 (15, suppl 1):  (abstract: 3643), 2013
Link
MGN1703 – structure of agonist determines cellular responses to TLR9 activation.Kapp K et al.
ASGCT 16th Annual Meeting (May 15 – May 18, 2013). (abstract: 686) 2013
Link
Can anthocyanins improve maintenance therapy
of Ph(+) acute lymphoblastic leukaemia?
Köchling J et al.
Eur J Haematol. 2013; 90(4): 291-300
Link
Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601.Grünwald V et al.
J Clin Oncol. 31 (6, suppl.): (abstract 468), 2013
Link

2012
Maintenance treatment with immunomodulator MGN1703 following induction with standard 1st line therapy prolongs progression-free survival in patients with metastatic colorectal (mCRC): results of the phase II/III IMPACT trial.Arnold D et al.
Ann Oncol. 23 (suppl. 9): ix178 (abstract: 518O), 2012
Link
The novel cancer vaccine, consisting of genetically modified allogeneic tumor cells and immunomodulator MGN1601: Updated results of
a phase 1-2 study in patients with advanced renal
cell carcinoma.
Schmidt-Wolf IGH et al.
Ann Oncol. 23 (suppl. 9): ix268 (abstract: 813P), 2012
Link
Prevention and synergistic control of Ph(+) ALL by
a DNA vaccine and 6-mercaptopurine.
Köchling J et al.
Vaccine. 2012; 30(41): 5949-55
Link
Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.Weikert S et al.
J Clin Oncol. 30 (15, suppl 1): (abstract: 4636), 2012
Link
Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-a-Expressing MIDGE Vector after Nonviral in Vivo Jet-Injection Gene Transfer.Galling et al.
Hum Gene Ther Methods. 23: 264-270, 2012
Link
Preliminary Safety Results from the IMPACT Study –
A Phase 2-3 Clinical Study in Patients with Advanced Colorectal Carcincoma with the Immunomodulator MGN1703.
Schmidt M et al.
Mol Ther. 20 (suppl. 1): S262 (abstract: 679), 2012
Link
New Safety and Efficacy Data of a Phase 1-2 Study
in Patients with Advanced Renal Cell Carcinoma, Following Vaccination with Fourfold Gene-Modified, Allogeneic Tumor Cells Combined with a DNA-Based Immunomodulator.
Weikert S et al.
Mol Ther. 20 (suppl 1): S129 (abstract: 327), 2012
Link
Immune-related efficacy data of the phase 1-2 study
of an with fourfold gene-modified allogeneic tumor
cell based vaccine in patients with advanced renal
cell carcinoma.
Weith E et al.
Cancer Res. 72 (8, suppl. 1): (abstract: LB-233), 2012
Link
New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.Grünwald V et al.
J Clin Oncol. 30 (5, suppl.): (abstract 398), 2012
Link
IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma.Tschaika M et al.
Clin Oncol. 30 (4, suppl.): (abstract: 633), 2012
Link

Archive
Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection.Endmann A et al.
Vaccine. 2010; 28(21): 3642-9
Link
Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia.Köchling J et al.
Vaccine. 2008; 26(36): 4669-75
Link
Minimal size MIDGE vectors improve transgene expression in vivo.Schakowski F et al.
In Vivo. 2007; 21(1):17-23
Link
MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity.Choi Y et al.
Int J Cancer. 2007; 120(9): 1942-50
Link
Effect of different nuclear localization sequences on
the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D.
Zheng C et al.
Vaccine. 2006; 24(21): 4625-9
Link
MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies, in Modern Biopharmaceuticals.Schmidt M et al.
J. Knäblein and R.H. Müller, Editors. 2005, WILEY-VCH Verlag GmbH&Co. KGaA: Weinheim. 1-29.
DNA immunisation with minimalistic expression constructs.Moreno S et al.
Vaccine. 2004; 22(13-14): 1709-16
Link
Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides.Köchling J et al.
Clin Cancer Res. 2003; 9(8): 3142-9
Link
DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. López-Fuertes L
et al.
Vaccine. 2002; 21(3-4): 247-57
Link
Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide.  Schirmbeck R et al.
J Mol Med (Berl). 2001; 79(5-6): 343-50
Link
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial.Wittig B et al.
Hum Gene Ther. 2001; 12(3): 267-78
Link
Form Follows Function, in Plasmid for Therapy and Vaccination.Junghans C et al.
M. Schleef,
Editor 2001, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim. 139-156

Share Subscription Facility with US investor GCF

Further Information

Related Links

Contact:

Dr. Mariola Söhngen

research@mologen.com